ORPHELIA reports positive results of the bioequivalence study of KIMOZO® (oral suspension of temozolomide) UncategorizedBy Charlotte Maddalena31 May 2022
ORPHELIA Pharma has been awarded a € 1 million grant from Bpifrance to develop a therapy for a rare form of epilepsy UncategorizedBy Charlotte Maddalena11 May 2022
